New insider activity at Glaukos ( (GKOS) ) has taken place on December 11, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Gilbert Kliman has recently sold 5,000 shares of Glaukos stock, amounting to a total transaction value of $536,350.
Recent Updates on GKOS stock
In the last 24 hours, Glaukos has seen positive developments as Citi and Needham both raised their price targets for the company. Citi increased its target due to an optimistic outlook for the medical technology sector, expecting a rebound driven by company catalysts and sector rotation. Needham’s adjustment was influenced by discussions with doctors who are optimistic about Glaukos’s products, particularly Epioxa, which could enhance treatment capacity and drive near-term upside. These factors contribute to the belief that Glaukos is poised for growth, leading to increased price targets.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
Glaukos’s strong sales growth and strategic product developments are significant positives. However, profitability challenges and valuation concerns weigh on the overall score. The technical indicators suggest bullish momentum, but caution is advised due to overbought signals.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
YTD Price Performance: -27.37%
Average Trading Volume: 1,137,361
Technical Sentiment Signal: Buy
Current Market Cap: $6.14B